Search Results - "Kam, Boen L"

Long-Term Efficacy, Survival, and Safety of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors by Brabander, Tessa, van der Zwan, Wouter A, Teunissen, Jaap J M, Kam, Boen L R, Feelders, Richard A, de Herder, Wouter W, van Eijck, Casper H J, Franssen, Gaston J H, Krenning, Eric P, Kwekkeboom, Dik J

“…Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell…”
Get full text

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival by KWEKKEBOOM, Dik J, DE HERDER, Wouter W, KAM, Boen L, VAN EIJCK, Casper H, VAN ESSEN, Martijn, KOOIJ, Peter P, FEELDERS, Richard A, VAN AKEN, Maarten O, KRENNING, Eric P

“…Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver…”
Get full text

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors by Kwekkeboom, Dik J, Kam, Boen L, van Essen, Martijn, Teunissen, Jaap J M, van Eijck, Casper H J, Valkema, Roelf, de Jong, Marion, de Herder, Wouter W, Krenning, Eric P

“…Somatostatin receptor imaging (SRI) with [111In-DTPA0]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine…”
Get full text

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls by Beukhof, Carolien M, Brabander, Tessa, van Nederveen, Francien H, van Velthuysen, Marie-Louise F, de Rijke, Yolanda B, Hofland, Leo J, Franssen, Gaston J H, Fröberg, Lideke A C, Kam, Boen L R, Visser, W Edward, de Herder, Wouter W, Peeters, Robin P

“…For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3-4 adverse…”
Get full text

Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors by KWEKKEBOOM, Dik J, TEUNISSEN, Jaap J, BAKKER, Willem H, KOOIJ, Peter P, DE HERDER, Wouter W, FEELDERS, Richard A, VAN EIJCK, Casper H, ESSER, Jan-Paul, KAM, Boen L, KRENNING, Eric P

“…There are few treatment options for patients with metastasized or inoperable endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but…”
Get full text

Peptide-receptor radionuclide therapy for endocrine tumors by van Essen, Martijn, Krenning, Eric P, Kam, Boen L. R, de Jong, Marion, Valkema, Roelf, Kwekkeboom, Dik J

“…Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, such as octreotide, is a promising option for the treatment of…”
Get full text

Serum microRNA profiles in athyroid patients on and off levothyroxine therapy by Massolt, Elske T, Chaker, Layal, Visser, Theo J, Gillis, Ad J M, Dorssers, Lambert C J, Beukhof, Carolien M, Kam, Boen L R, Franssen, Gaston J, Brigante, Giulia, van Ginhoven, Tessa M, Visser, W Edward, Looijenga, Leendert H J, Peeters, Robin P

“…Levothyroxine replacement treatment in hypothyroidism is unable to restore physiological thyroxine and triiodothyronine concentrations in serum and tissues…”
Get full text

Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors by Kwekkeboom, Dik J., MD, PhD, de Herder, Wouter W., MD, PhD, van Eijck, Casper H.J., MD, PhD, Kam, Boen L., MD, van Essen, Martijn, MD, Teunissen, Jaap J.M., MD, PhD, Krenning, Eric P., MD, PhD

“…Somatostatin receptor imaging with [111 In-DTPA0 )octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors…”
Get full text

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate by de Keizer, Bart, van Aken, Maarten O., Feelders, Richard A., de Herder, Wouter W., Kam, Boen L. R., van Essen, Martijn, Krenning, Eric P., Kwekkeboom, Dik J.

“…Introduction Receptor radionuclide therapy is a promising treatment modality for patients with neuroendocrine tumors for whom alternative treatments are…”
Get full text

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study by Kloth, Jacqueline S. L., Klümpen, Heinz-Josef, Yu, Huixin, Eechoute, Karel, Samer, Caroline F., Kam, Boen L. R., Huitema, Alwin D. R., Daali, Youssef, Zwinderman, Aeilko H., Balakrishnar, Bavanthi, Bennink, Roelof J., Wong, Mark, Schellens, Jan H. M., Mathijssen, Ron H. J., Gurney, Howard

“…Background and Objective The wide inter-patient variability in drug exposure partly explains the toxicity and efficacy profile of sunitinib treatment. In this…”
Get full text

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial) by Braat, Arthur J. A. T, Kwekkeboom, Dik J, Kam, Boen L. R, Teunissen, Jaap J. M, de Herder, Wouter W, Dreijerink, Koen M. A, van Rooij, Rob, Krijger, Gerard C, de Jong, Hugo W. A. M, van den Bosch, Maurice A. A. J, Lam, Marnix G. E. H

“…Background Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a…”
Get full text

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy by van Vliet, Esther I, Teunissen, Jaap J M, Kam, Boen L R, de Jong, Marion, Krenning, Eric P, Kwekkeboom, Dik J

“…The primary treatment of gastroenteropancreatic neuroendocrine tumors (GEPNETs) is surgery with curative intent or debulking of the tumor mass. In case of…”
Get more information

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs by Bergsma, Hendrik, MD, PhD, van Vliet, Esther I., MD, PhD, Teunissen, Jaap J.M., MD, PhD, Kam, Boen L.R., MD, de Herder, Wouter W., MD, PhD, Peeters, Robin P., MD, PhD, Krenning, Eric P., MD, PhD, Kwekkeboom, Dik J., MD, PhD

“…Abstract Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with…”
Get full text

Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate by van Vliet, Esther I., de Herder, Wouter W., de Rijke, Yolanda B., Zillikens, M. Carola, Kam, Boen L. R., Teunissen, Jaap J. M., Peeters, Robin P., Krenning, Eric P., Kwekkeboom, Dik J.

“…Purpose The aim of this study was to explore the possible mechanisms involved in an observed decline in serum calcium levels in patients with a neuroendocrine…”
Get full text

[(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy by Pool, Stefan E, Kam, Boen L R, Koning, Gerben A, Konijnenberg, Mark, Ten Hagen, Timo L M, Breeman, Woulter A P, Krenning, Eric P, de Jong, Marion, van Eijck, Casper H J

“…With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we…”
Get more information

Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer by Simons, Janine M, van Nijnatten, Thiemo J A, van der Pol, Carmen C, van Diest, Paul J, Jager, Agnes, van Klaveren, David, Kam, Boen L R, Lobbes, Marc B I, de Boer, Maaike, Verhoef, Cees, Sars, Paul R A, Heijmans, Harald J, van Haaren, Els R M, Vles, Wouter J, Contant, Caroline M E, Menke-Pluijmers, Marian B E, Smit, Léonie H M, Kelder, Wendy, Boskamp, Marike, Koppert, Linetta B, Luiten, Ernest J T, Smidt, Marjolein L

“…Several less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients…”
Get more information

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate by Khan, Saima, Krenning, Eric P, van Essen, Martijn, Kam, Boen L, Teunissen, Jaap J, Kwekkeboom, Dik J

“…Quality of life (QOL) is an important outcome in cancer therapy. In this study, we investigated the QOL and symptoms after [(177)Lu-DOTA(0),Tyr(3)]octreotate…”
Get full text

Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer by van Velsen, Evert F S, Stegenga, Merel T, van Kemenade, Folkert J, Kam, Boen L R, van Ginhoven, Tessa M, Visser, W Edward, Peeters, Robin P

“…Recently, the eighth edition of the American Joint Committee on Cancer (AJCC)/tumor node metastasis (TNM) staging system for differentiated thyroid cancer…”
Get more information

Longitudinal analysis of quality of life in patients treated for differentiated thyroid cancer by van Velsen, Evert F S, Massolt, Elske T, Heersema, Hélène, Kam, Boen L R, van Ginhoven, Tessa M, Visser, W Edward, Peeters, Robin P

“…Objective Earlier cross-sectional studies showed that patients with differentiated thyroid cancer (DTC) have a significant reduction of quality of life (QoL)…”
Get full text

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate by van Vliet, Esther I, van Eijck, Casper H, de Krijger, Ronald R, Nieveen van Dijkum, Elisabeth J, Teunissen, Jaap J, Kam, Boen L, de Herder, Wouter W, Feelders, Richard A, Bonsing, Bert A, Brabander, Tessa, Krenning, Eric P, Kwekkeboom, Dik J

“…Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for which surgery has almost the only potential for cure. When surgery is not possible because of…”
Get full text